NCT06987539 2026-03-16
THYME
Amgen
Phase 2 Recruiting
Clinical Trials
20 trialsNCT06414954 2026-03-10
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
NCT07284420 2026-02-09
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT06282159 2025-10-07
MAGIC
Dianthus Therapeutics
Phase 2 Active not recruiting
NCT04226170 2025-09-11
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
DAS-MG, Inc
Phase 2 Terminated
NCT04146051 2025-05-28
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Cartesian Therapeutics
Phase 2 Active not recruiting
NCT05218096 2025-01-09
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02965573 2024-08-28
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
Phase 2 Completed
NCT03863080 2023-12-20
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Immunovant Sciences GmbH
Phase 2 Completed
NCT03772587 2023-06-27
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Completed
NCT03896295 2023-06-27
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Terminated
NCT04159805 2023-06-02
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Takeda
Phase 2 Completed
NCT04346888 2023-03-08
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 2 Completed
NCT03315130 2022-07-27
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT04982289 2022-02-11
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT03052751 2021-08-03
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT02473965 2020-03-30
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed
NCT00727194 2019-09-24
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
NCT01268280 2019-09-24
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Cytokinetics
Phase 2 Terminated
NCT02473952 2019-03-05
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed